Brief: Strides Pharma Science Strides Flagship Facility In Bangalore Receives USFDA Inspection Closure
Feb 24 (Reuters) - Strides Pharma Science Ltd SRID.NS :
* STRIDES FLAGSHIP FACILITY IN BANGALORE RECEIVES USFDA
INSPECTION
CLOSURE
* USFDA HAS CLASSIFIED OUTCOME OF THIS INSPECTION AS
VOLUNTARY
ACTION INDICATED
Source text for Eikon: ID:nBSEbLC347
Further company coverage: SRID.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Strides Pharma Science
See all newsIndia's Strides Pharma jumps on successful closure of USFDA inspection at Bengaluru facility
Brief: Strides Pharma Science Receives USFDA EIR For Flagship Facility In Bengaluru
Brief: Strides Pharma Science Receives US FDA Establishment Inspection Report For Bengaluru Facility
Brief: Strides Pharma Science June-Quarter Consol Net Profit 1.57 Billion Rupees
Brief: Strides Pharma Science March-Quarter Consol Net Profit 1.27 Billion Rupees